Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Netherlands
  4. Euronext Amsterdam
  5. Galapagos NV
  6. News
  7. Summary
    GLPG   BE0003818359

GALAPAGOS NV

(GLPG)
  Report
Real-time Euronext Amsterdam  -  11:35 2022-10-06 am EDT
44.55 EUR   +0.13%
10/04Galapagos Says It Secured Positive Regulatory Opinion on Jyseleca's European Label Update -- Shares Rise Tuesday
MT
10/03Galapagos Wins EU Health Agency Backing To Remove Male Fertility Warning On Jyseleca's Label
MT
10/03Galapagos NV Says It Secures Positive Regulatory Opinion on Jyseleca's European Label Update
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Transcript : Galapagos NV, Q1 2022 Earnings Call, May 06, 2022

05/06/2022 | 08:00am EDT
Good day, and thank you for standing by. Welcome to the Galapagos Financial Results Q1 2022 Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded....


© S&P Capital IQ 2022
All news about GALAPAGOS NV
10/04Galapagos Says It Secured Positive Regulatory Opinion on Jyseleca's European Label Upda..
MT
10/03Galapagos Wins EU Health Agency Backing To Remove Male Fertility Warning On Jyseleca's ..
MT
10/03Galapagos NV Says It Secures Positive Regulatory Opinion on Jyseleca's European Label U..
MT
10/03Galapagos receives positive CHMP opinion for Jyseleca® European label update based on t..
GL
10/03Galapagos receives positive CHMP opinion for Jyseleca® European label update based on t..
AQ
10/03Galapagos Receives Positive CHMP Opinion for Jyseleca® European Label Update Based on T..
CI
09/27Galapagos increases share capital through subscription right exercises
GL
09/27Galapagos increases share capital through subscription right exercises
AQ
09/27Galapagos NV announced that it has received €3.07625 million in funding
CI
09/09Morgan Stanley Downgrades Galapagos to Equalweight From Overweight, Cuts Price Target t..
MT
More news
Analyst Recommendations on GALAPAGOS NV
More recommendations
Financials
Sales 2022 536 M 528 M 528 M
Net income 2022 -148 M -146 M -146 M
Net cash 2022 3 502 M 3 452 M 3 452 M
P/E ratio 2022 -26,2x
Yield 2022 -
Capitalization 2 929 M 2 888 M 2 888 M
EV / Sales 2022 -1,07x
EV / Sales 2023 -0,55x
Nbr of Employees 1 344
Free-Float 73,9%
Chart GALAPAGOS NV
Duration : Period :
Galapagos NV Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GALAPAGOS NV
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 7
Last Close Price 44,49 €
Average target price 59,29 €
Spread / Average Target 33,3%
EPS Revisions
Managers and Directors
Paulus Stoffels Chairman & Chief Executive Officer
Bart Filius President, Chief Operating & Financial Officer
Walid Abi-Saab Chief Medical Officer
Howard Mitchell Rowe Independent Non-Executive Director
Katrine S. Bosley Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
GALAPAGOS NV-9.61%2 888
MODERNA, INC.-50.54%49 142
LONZA GROUP AG-33.72%38 001
IQVIA HOLDINGS INC.-31.78%35 901
SEAGEN INC.-11.47%25 244
ALNYLAM PHARMACEUTICALS, INC.18.67%24 128